Management outlined a post-Jakafi growth strategy centered on a robust late-stage pipeline in hematology, oncology, and immunology, with multiple billion-dollar opportunities. Key assets include 989 for MPNs, Opzelura’s global expansion, povorcitinib for HS and PN, and solid tumor programs, all supported by strong execution and business development.
Based on Incyte Corporation [INCY] Citi Annual Global Healthcare Conference 2025 Audio Transcript — Dec. 2 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
